Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aslan Pharmaceuticals Ltd ADR

ASLN
Current price
0.45 USD -0.015 USD (-3.22%)
Last closed 0.47 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 10 611 969 USD
Yield for 12 month -88.04 %
1Y
3Y
5Y
10Y
15Y
ASLN
21.11.2021 - 28.11.2021

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore. Address: 3 Temasek Avenue, Singapore, Singapore, 039190

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

9.5 USD

P/E ratio

Dividend Yield

Current Year

+12 000 000 USD

Last Year

+12 000 000 USD

Current Quarter

Last Quarter

Current Year

+11 651 502 USD

Last Year

-331 752 USD

Current Quarter

Last Quarter

Key Figures ASLN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -43 706 824 USD
Operating Margin TTM -364.46 %
PE Ratio
Return On Assets TTM -63.71 %
PEG Ratio
Return On Equity TTM -426.64 %
Wall Street Target Price 9.5 USD
Revenue TTM 12 000 000 USD
Book Value -0.76 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM 79 821 000 USD
Earnings per share -2.75 USD
Diluted Eps TTM -2.75 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ASLN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ASLN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:5
Payout Ratio
Last Split Date 13.03.2023
Dividend Date

Stock Valuation ASLN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.7356
Price Sales TTM 0.9432
Enterprise Value EBITDA -0.2158
Price Book MRQ 2.1426

Financials ASLN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ASLN

For 52 weeks

0.39 USD 4.26 USD
50 Day MA 0.52 USD
Shares Short Prior Month 700 394
200 Day MA 0.95 USD
Short Ratio 0.56
Shares Short 302 222
Short Percent 1.12 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.16 USD Microsoft Corporation +3.16 (+0.74%)
Detailed analytics

ETF funds


S

SX7EEX

14.70 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.1 (+0.64%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics